This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Jazz Pharmaceuticals plc
Drug Names(s): sodium oxybate, JZP-6, gamma-hydroxybutyric (GHB)
Description: BioMedTracker has separate drug profiles for sodium oxybate. Please also see Xyrem.
JZP-6 is a liquid dosage form of sodium oxybate, the active pharmaceutical ingredient in Xyrem (the concentrations are different: 375 mg/mL for JZP-6 versus 500 mg/mL for Xyrem; the upper end of the recommended dose range is also different: 6 g for JZP-6 versus 9 g for Xyrem).
Deal Structure: In June 2006, Jazz amended its agreement with UCB to grant UCB the right to market JZP-6 for the treatment of FMS in 54 countries throughout Europe, South America, the Middle East and Asia. Under the terms of the amended agreement, UCB paid Jazz $15.0 million to develop and commercialize JZP-6 for the treatment of FMS. Jazz is entitled to up to $40.0 million in itional developmental milestone payments associated with JZP-6, and itional commercial milestone payments of up to $100.0 million related primarily to JZP-6 for the treatment of FMS as well as Xyrem for the treatment of narcolepsy. Royalties are the same as for Xyrem, starting at 15% of net sales.
The term of Jazz's agreement with UCB, as it applies to JZP-6, extends to the earlier of the expiration of its associated patent rights in the territories covered by the agreement or ten years from the date of EMEA approval to commercially promote and distribute the product for the treatment of FMS, subject to automatic renewals...See full deal structure in Biomedtracker
Partners: UCB SA
Additional information available to subscribers only: